SEK 000s Q321/22 Q320/21 May-Jan 21/22 May-Jan 20/21 Full year20/21 Net sales 314 1,376 963 1,759 2,077 Operating profit (loss) -14,417 -11,062 -40,970 -28,012 -40,181 Profit (loss) for the period -14,334 -10,909 -40,947 -27,491 -39,482 Earnings per share, after dilution -0.50 -0.38 -1.44 -0.97 -1.39 Significant events during the third quarter Article on the DiviTum®TKa […]
Biovica, active in cancer diagnostics, today announces that the company will establish its own US CLIA lab for the launch of DiviTum®TKa on the US market. Biovica aims to have its lab operational and CLIA certified during third quarter 2022.
The Nomination Committee prior to the 2022 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2021, and the Chairman of the Board. The Nomination Committee then appoints a chairman among its members.
Biovica, active in cancer diagnostics, today announces that the positive DiviTum®TKa results from the European multicenter study PYTHIA have been published in the highly ranked peer-reviewed scientific journal European Journal of Cancer (EJC). The results demonstrate a predictive capacity of the assay after only two weeks of treatment and supports the use of DiviTum®TKa for optimized information and early therapy efficacy evaluation in metastatic breast cancer.
Biovica, active in cancer diagnostics, today announces that it has received full feedback from the FDA on its updated 510(k)-application enabling a clear plan for the submission process. Biovica is now aiming for submission in May 2022.
SEK 000s Q221/22 Q220/21 May-Oct 21/22 May-Oct 20/21 Full year20/21 Net sales 268 44 649 384 2,077 Operating profit (loss) -14,314 -8,285 -26,552 -16,950 -40,181 Profit (loss) for the period -14,388 -8,208 -26,613 -16,581 -39,482 Earnings per share after dilution -0.51 -0.29 -0.93 -0.59 -1.39 Significant events during the second quarter Biovica has strengthened its […]
Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica’s blood-based biomarker assay DiviTum®TKa on monitoring practices in the care of metastatic breast cancer patients.
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world’s largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.
Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model’s results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra spend relative to current management of metastatic breast cancer patients.
The extra general meeting of Biovica International AB (“Biovica” or the “Company”) was held today on 12 October 2021 and the following resolutions were passed by the meeting.